Clinical Trial Detail

NCT ID NCT03940352
Title HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

HDM201 + Venetoclax

HDM201 + Sabatolimab

Age Groups: senior adult

No variant requirements are available.